Keymed Biosciences secures NMPA approval for Stapokibart in chronic rhinosinusitis treatment
Keymed Biosciences Inc. (HKEX: 02162) has received a significant regulatory endorsement as the National Medical Products Administration (NMPA) of China approved its supplemental New Drug ... Read More